TMO · 10-Q · 2026Q3 · Full report

Acquisitions and Divestitures

THERMO FISHER SCIENTIFIC INC. · 2026-10-30 · Importance 65 · Surprise 60

On March 24, 2026, Thermo Fisher acquired Clario Holdings, a U.S. clinical-trial endpoint data provider, for its Laboratory Products and Biopharma Services segment. The acquisition contributed to $425 million of third-quarter reported clinical research business growth and approximately $1.05 billion of nine-month reported growth in that business. On August 12, 2026, the company sold its Specialty Diagnostics microbiology business to Astorg, receiving $1.02 billion in cash during the first nine months of 2026. The company also acquired the Solventum filtration and separation business on September 1, 2025, strengthening Life Sciences Solutions’ bioproduction offerings; acquisitions used $8.88 billion of cash in the first nine months of 2026.

Key facts

• In the first nine months of 2026, Thermo Fisher Scientific Inc.’s acquisitions used $8.88 billion of cash, and proceeds from the microbiology business sale provided $1.02 billion. source
• On March 24, 2026, Thermo Fisher Scientific Inc. acquired Clario Holdings, Inc. for its Laboratory Products and Biopharma Services segment; Clario provides endpoint data solutions for clinical trials, and the acquisition expanded the segment’s clinical research offerings. source
• In the first nine months of 2025, Thermo Fisher Scientific Inc.’s acquisitions used $4.04 billion of cash. source
• On September 1, 2025, Thermo Fisher Scientific Inc. acquired a filtration and separation business from Solventum Corporation for its Life Sciences Solutions segment. source
• On August 12, 2026, Thermo Fisher Scientific Inc. sold its microbiology business, which was part of the Specialty Diagnostics segment, to Astorg. source